Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial

Rudra Paul; Arijit Ghosh; Nilanjan Sengupta; Pranab Kumar Sahana

doi:10.5455/njppp.2022.12.062851202217862022

2024, Vol: 14, Issue: 10

14 / 10Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research
Online Published: 27 Jun 2022

Natl J Physiol Pharm Pharmacol. 2022; 12(8): 1229-1232

doi: 10.5455/njppp.2022.12.062851202217862022

Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial

Rudra Paul, Arijit Ghosh, Nilanjan Sengupta, Pranab Kumar Sahana.

Abstract
Background: Type 2 diabetes mellitus (DM) is mainly due to multifactorial of which insulin resistance and deficiency in the incretion are two important pathophysiological factors. Vildagliptin, an oral hypoglycemic agent, acts by inhibiting dipeptidyl peptidase-4 enzyme, often uses as a first line drug along with metformin to enhance outcome.

Aim and Objective: The aim of this study was to compare the effectiveness and safety of vildagliptin 50 mg twice daily dose with vildagliptin 100 mg sustained release tablet (SR) once daily in Type 2 DM patients and uncontrolled with metformin monotherapy.

Materials and Methods: Adult patients with Type 2 DM fulfilling the inclusion criteria were randomized in two groups. Group 1 patient received metformin 1000 mg/day in two divided dose and tablet vildagliptin 50 mg 2 times daily, while Group 2 patients received metformin 1000 mg/day in two divided dose along with vildagliptin 100 mg SR once daily. Fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), and glycated hemoglobin (HbA1C), were measured at baseline, on week 4, week 8, and week 12 visits. Liver function test (SGOT), SGPT, Serum Bilirubin), kidney function test electrolytes, serum urea, serum creatinine), and body weight also measured in first visit and in 12th week.

Results: HbA1C, FPG, and PPPG all three decreased equally at 12 week from their respective baseline values (P < 0.05) in both groups. There is no statistically significant alteration of liver enzymes and in serum bilirubin level from baseline to 12th week in both groups.

Conclusion: Vildagliptin 100 mg SR once daily dose is equally effective and safe as 50 mg twice daily dose in terms of reducing HbA1C, FPG, and PPPG when it is used along with metformin 1000 mg.

Key words: Vildagliptin; Type 2 Diabetes Mellitus; Efficacy

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Rudra Paul Articles by Arijit Ghosh Articles by Nilanjan Sengupta Articles by Pranab Kumar Sahana
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Paul R, Ghosh A, Sengupta N, Sahana PK. Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial. Natl J Physiol Pharm Pharmacol. 2022; 12(8): 1229-1232. doi:10.5455/njppp.2022.12.062851202217862022

Web Style

Paul R, Ghosh A, Sengupta N, Sahana PK. Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial. https://www.njppp.com/?mno=55832 [Access: October 03, 2024]. doi:10.5455/njppp.2022.12.062851202217862022

AMA (American Medical Association) Style

Paul R, Ghosh A, Sengupta N, Sahana PK. Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial. Natl J Physiol Pharm Pharmacol. 2022; 12(8): 1229-1232. doi:10.5455/njppp.2022.12.062851202217862022

Vancouver/ICMJE Style

Paul R, Ghosh A, Sengupta N, Sahana PK. Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial. Natl J Physiol Pharm Pharmacol. (2022), [cited October 03, 2024]; 12(8): 1229-1232. doi:10.5455/njppp.2022.12.062851202217862022

Harvard Style

Paul, R., Ghosh, . A., Sengupta, . N. & Sahana, . P. K. (2022) Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial. Natl J Physiol Pharm Pharmacol, 12 (8), 1229-1232. doi:10.5455/njppp.2022.12.062851202217862022

Turabian Style

Paul, Rudra, Arijit Ghosh, Nilanjan Sengupta, and Pranab Kumar Sahana. 2022. Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial. National Journal of Physiology, Pharmacy and Pharmacology, 12 (8), 1229-1232. doi:10.5455/njppp.2022.12.062851202217862022

Chicago Style

Paul, Rudra, Arijit Ghosh, Nilanjan Sengupta, and Pranab Kumar Sahana. "Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 1229-1232. doi:10.5455/njppp.2022.12.062851202217862022

MLA (The Modern Language Association) Style

Paul, Rudra, Arijit Ghosh, Nilanjan Sengupta, and Pranab Kumar Sahana. "Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial." National Journal of Physiology, Pharmacy and Pharmacology 12.8 (2022), 1229-1232. Print. doi:10.5455/njppp.2022.12.062851202217862022

APA (American Psychological Association) Style

Paul, R., Ghosh, . A., Sengupta, . N. & Sahana, . P. K. (2022) Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial. National Journal of Physiology, Pharmacy and Pharmacology, 12 (8), 1229-1232. doi:10.5455/njppp.2022.12.062851202217862022

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article